Pharmacokinetics of high dose melphalan

Area of Science:

• Pharmacology
• Clinical Pharmacokinetics
• Oncology Drug Metabolism

Background:

• Melphalan is a chemotherapy agent used in treating various cancers.
• Understanding the pharmacokinetics of high-dose melphalan is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

• To characterize the pharmacokinetic profile of high-dose intravenous melphalan (180 mg/m2).
• To compare the kinetic parameters of high-dose melphalan with those previously reported for lower doses.

Main Methods:

• A pharmacokinetic study involving eight patients receiving high-dose intravenous melphalan (180 mg/m2).
• Analysis of plasma melphalan concentrations over time to determine key pharmacokinetic parameters.

Main Results:

• Plasma melphalan levels exhibited biexponential decline.
• Mean terminal half-life (t 1/2 beta) was 61 minutes (range: 40.3-132.8 min).
• Estimated peak concentrations ranged from 5.45 to 16.57 mcg/ml, with Vdss of 0.479 +/- 0.164 l/kg and clearance of 6.73 +/- 1.60 ml/min/kg.

Conclusions:

• The pharmacokinetic parameters of high-dose intravenous melphalan are comparable to those observed with lower doses.
• These findings suggest consistent melphalan disposition across different dose levels, informing clinical dosing strategies.